Vanda Pharmaceuticals’ (VNDA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $18.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Thursday, December 19th. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Stock Performance

VNDA opened at $4.68 on Monday. The stock’s 50 day moving average price is $4.86 and its 200-day moving average price is $5.21. Vanda Pharmaceuticals has a 52-week low of $3.46 and a 52-week high of $6.75. The stock has a market capitalization of $272.88 million, a PE ratio of -16.71 and a beta of 0.76.

Insider Transactions at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the sale, the director now directly owns 44,857 shares of the company’s stock, valued at $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in shares of Vanda Pharmaceuticals by 1,184.6% during the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 57,393 shares in the last quarter. Monaco Asset Management SAM purchased a new position in Vanda Pharmaceuticals during the second quarter valued at $1,090,000. FMR LLC boosted its holdings in Vanda Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock worth $702,000 after acquiring an additional 30,802 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in shares of Vanda Pharmaceuticals in the third quarter worth $864,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Vanda Pharmaceuticals by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock valued at $11,379,000 after acquiring an additional 292,172 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.